PDT Partners’s Arbutus Biopharma ABUS Stock Holding History

PDT Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-72,500	Closed	-$241K	–	778
2021 Q1	$241K	Buy	+72,500	New	+$280K	0.02%	661
2019 Q2	–	Sell	-30,200	Closed	-$108K	–	409
2019 Q1	$108K	Hold	30,200	–	–	0.01%	413
2018 Q4	$116K	Buy	30,200 +6,150	+26%	+$30.3K	0.01%	436
2018 Q3	$227K	Sell	24,050 -42,915	-64%	-$426K	0.01%	422
2018 Q2	$489K	Sell	66,965 -5,535	-8%	-$32.9K	0.02%	401
2018 Q1	$363K	Sell	72,500 -10,500	-13%	-$55.6K	0.01%	475
2017 Q4	$419K	Buy	+83,000	New	+$487K	0.01%	451
2016 Q4	–	Sell	-22,800	Closed	-$78K	–	494
2016 Q3	$78K	Sell	22,800 -7,400	-25%	-$28.9K	﹤0.01%	468
2016 Q2	$105K	Buy	+30,200	New	+$128K	0.01%	427
2015 Q3	–	Sell	-20,794	Closed	-$247K	–	1227
2015 Q2	$247K	Buy	+20,794	New	+$316K	0.01%	1187

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

PDT Partners's ABUS Position: Q2 2021 in Review

PDT Partners sold out of Arbutus Biopharma (ABUS) in Q2 2021, closing a stake of 72,500 shares — an estimated $241K sold.

PDT Partners first reported a position in ABUS in Q2 2015 and held it in 10 quarters. The position peaked at $489K in Q2 2018. 91 funds tracked by Wall St. Rank hold ABUS as of Q2 2021.

PDT Partners reported no remaining Arbutus Biopharma position as of Q2 2021 after selling out during the quarter.
PDT Partners sold 72,500 Arbutus Biopharma shares in Q2 2021, an estimated $241K.
PDT Partners first reported a position in Arbutus Biopharma in Q2 2015 and held it in 10 quarters.
PDT Partners's Arbutus Biopharma position peaked at $489K in Q2 2018.
91 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2021.

Based on PDT Partners's 13F filing for Q2 2021, filed 16 Aug 2021.